Proteomics International Laboratories (ASX:PIQ) — Material Events
ASX:PIQ · 22 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Proteomics International Secures US Patent for Breakthrough Esophageal Cancer TestMedium
Proteomics International secures US patent for PromarkerEso diagnostic test for esophageal cancer
17 Dec 2025
·Patent Grant Announcement
·85
CMS Sets $390 Medicare Price for PromarkerD, Paving US Market EntryMedium
CMS sets US$390.75 reimbursement for Proteomics International's PromarkerD test, boosting US launch
26 Nov 2025
·ASX Release
·85
Proteomics International’s Blood Test Detects Early Esophageal Cancer with High AccuracyMedium
Proteomics International's PromarkerEso blood test accurately detects early esophageal cancer stages
8 Sept 2025
·ASX Release
·85
Proteomics International Accelerates US Launch of PromarkerD After $12M RaiseHigh
Proteomics International raises $12M, launches PromarkerD in USA, advances diagnostic tests with new patents and funding
28 July 2025
·Quarterly Activities Report
·85
Proteomics International Accelerates Precision Diagnostics with New Test Launches and ISO CertificationMedium
Proteomics International advances precision diagnostics with new test launches, ISO certification, US reimbursement code, and management transition
27 Oct 2025
·Quarterly Activities Report
·85
Proteomics International Boosts Endometriosis Test Collaboration Ahead of LaunchMedium
Proteomics International expands collaboration to advance PromarkerEndo blood test for endometriosis diagnosis
15 Oct 2025
·Collaboration Expansion Announcement
·85
WA Government Grants $0.5M to Fast-Track PromarkerEndo Blood Test for EndometriosisMedium
Proteomics International awarded $0.5M WA Government grant to commercialise PromarkerEndo blood test for endometriosis
6 Nov 2025
·Grant Funding Announcement
·80
How OxiDx’s Oxidative Stress Test Boosts Racehorse Wins by Nearly 50%Medium
OxiDx test links oxidative stress biomarker to improved Thoroughbred racehorse performance
24 Nov 2025
·ASX Release
·80
Proteomics International Secures CAP Accreditation, Boosting US Diagnostic AmbitionsMedium
Proteomics International secures CAP accreditation and installs mass spec platform to accelerate US commercialisation
24 Dec 2025
·ASX Release
·80
Proteomics International Secures Canadian Patent for Breakthrough Esophageal Cancer TestMedium
Proteomics International secures Canadian patent for PromarkerEso diagnostic test for esophageal cancer
16 Jan 2026
·Patent Grant Announcement
·80
Proteomics International Advances Commercial Launch of Diagnostic Tests with Distributor ModelMedium
Proteomics International advances commercial rollout of validated diagnostic tests with distributor model and reimbursement focus
28 Apr 2026
·Strategic Update Presentation
·80
Proteomics International Secures US Patent for PromarkerEndo Endometriosis TestMedium
Proteomics International secures US patent for PromarkerEndo endometriosis diagnostic test
8 July 2026
·Patent Grant Announcement
·75
Proteomics International Attributes Price Surge to Medicare Reimbursement and Product MilestonesMedium
Proteomics International clarifies no undisclosed info amid price surge, cites recent Medicare pricing and product milestones
2 Dec 2025
·Price Query Response
·75
Proteomics International Secures ISO 15189 Certification, Boosting Diagnostic Test RolloutMedium
Proteomics International achieves ISO 15189 certification, advancing precision diagnostic test commercialisation
18 Sept 2025
·Certification Announcement
·75
PromarkerD Validated for Early Kidney Disease Prediction in Aboriginal AustraliansMedium
PromarkerD test validated for predicting diabetic kidney disease in Aboriginal Australians
15 Dec 2025
·Clinical Study Announcement
·75
How Proteomics International’s OxiDx Test Revolutionises Racehorse Muscle RecoveryMedium
Proteomics International's OxiDx test detects muscle damage in racehorses, commercial launch planned for H2 2025
14 July 2025
·ASX Release
·75
Proteomics International Boosts Cash with $2.2M R&D Tax IncentiveMedium
Proteomics International secures $2.2M R&D tax incentive to advance diagnostic test pipeline
12 Nov 2025
·ASX announcement
·70
Proteomics International Taps David Morris to Accelerate Promarker® GrowthMedium
Proteomics International appoints David Morris as new CEO to drive Promarker® commercialisation
14 Jan 2026
·Executive Appointment
·70
Proteomics International Founder to Retire After 25 Years, CEO Search UnderwayMedium
Proteomics International MD Dr Richard Lipscombe to retire in Feb 2026; CEO search underway
9 Sept 2025
·Board and Management Transition
·70
Proteomics International Denies Undisclosed Info Amid Strategic Overhaul and Share VolatilityMedium
Proteomics International denies undisclosed info amid share price drop, cites recent strategic updates
7 May 2026
·Price Query Response
·70
Proteomics International Cuts 25% Staff, Appoints CFO, Signals Commercial ShiftMedium
Proteomics International restructures with 25% job cuts, appoints new CFO, and announces board retirement
17 Apr 2026
·Organisational Restructure and Executive Appointment
·70
Proteomics International’s Loss Widens Amid Promarker® Commercial PushMedium
Proteomics International reports increased loss and higher operational costs in FY2025
27 Aug 2025
·Preliminary Final Report
·60
No articles in this tier for the last 12 months.
Market Mentions
4
- appeared in market wrap coverage
These are market wrap articles where Proteomics International Laboratories (ASX:PIQ) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 28 (6 July -> 10 July) 2026
11 July 2026
Healthcare Wrap - Week 19 (4 May -> 8 May) 2026
9 May 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026